Dr. Martina RossiPhDThere has been steady interest in CJC-1295 research among researchers involved in somatotropic axis studies, peptide pharmacokinetics studies, and growth hormone (GH) secretory regulation. But what is CJC-1295? CJC-1295 is a synthetic variant of growth hormone-releasing hormone (GHRH) engineered for a much longer duration of action than the original hormone. This article will discuss the peptide structure of CJC-1295, the drug-affinity complex model of which it is part, and the physiological effects it exerts upon binding to GHRH receptors in the somatotropic axis. The information presented here is based on the preclinical literature and does not represent expected results in human subjects.
Natural GHRH is a hypothalamic hormone composed of 44 amino acids; of which, the first 29 amino residues, GRF(1-29), maintain their physiological effects on the GHRH receptor. CJC-1295 is constructed on this 1-29 backbone. According to Jette et al.,[1] the synthetic peptide contains a few amino acid modifications [D-Ala2, Gln8, Ala15, Leu27] that protect it from enzymatic breakdown, which rapidly clears native GHRH. The modification at position 2, in particular, confers resistance to rapid cleavage by dipeptidyl peptidase-4, an enzyme that rapidly inactivates the natural GRF(1-29) in blood plasma; others minimize proteolytic activity at specific cleavage sites. This core structure is also known as modified GRF(1-29). On its own, it is a more stable analog of GHRH, though still short-acting relative to the form that carries the Drug Affinity Complex (DAC).
What distinguishes CJC-1295 is its ability to form a DAC. Specifically, in the DAC form, the GRF(1-29)-modified analog contains a reactive chemical group, a maleimido-based linker that covalently binds to circulating serum albumin upon entering the bloodstream by reacting with a cysteine residue on albumin. Since albumin is highly abundant and relatively stable, linking the peptide to albumin serves the dual purpose of protecting the analog from rapid elimination and extending the duration of action of this otherwise short half-life fragment of GHRH to days. Jette et al.[1] identified this albumin bioconjugate as CJC-1295 and showed in rats that it still activates the GHRH (GRF) receptor on the anterior pituitary, confirming that binding to albumin does not stop it from acting at the receptor. Arguments surrounding CJC-1295 with or without DAC can thus be viewed as arguments for the same concept.
The mechanism of action of CJC-1295 is similar to that of GHRH itself. The receptor for GHRH is a class B G protein-coupled receptor found in the somatotroph cells in the anterior pituitary gland. As described by Mayo,[2] agonist binding couples to the stimulatory G protein (Gs), activates adenylyl cyclase, raises intracellular cyclic AMP, and drives both the synthesis and the pulsatile release of growth hormone. GH then stimulates hepatic production of insulin-like growth factor 1 (IGF-1), the main circulating mediator of GH's effects, which feeds back to restrain the axis. By engaging this receptor with a long half-life, CJC-1295 acts as a growth hormone secretagogue of the GHRH class, distinct from the ghrelin-mimetic secretagogues that work through a separate receptor.
Preclinical research on CJC-1295 established both the receptor action and the molecule's longevity. The foundational study by Jette et al.[1] on rats revealed that the albumin-conjugated analog could reach the pituitary gland, activate the GRF receptor, and induce a long-lasting increase in GH and IGF-1 compared to GRF(1-29). Alba and colleagues[3] then tested the analog in a GHRH-knockout mouse, an animal that cannot make its own GHRH and is therefore growth-retarded. Once-daily administration over several weeks led to normalization of growth and repair of the GH/IGF-1 axis in these animals, demonstrating that the analog can serve as a functional replacement for the absent native hormone. These are animal findings in controlled models, not an outcome to be expected in people.
Human research on CJC-1295 is minimal and should be read as entirely separate from the animal work. Only a handful of small, early-phase pharmacology studies in healthy volunteers exist, and they were designed to characterize how the analog behaves in the body rather than to test any health outcome. There are no large or long-term controlled trials, independent replication is limited, and there is no approved indication. As of 2026, CJC-1295 is not an approved drug. Readers should treat any extrapolation from this early pharmacology to a real-world human outcome as unsupported.
The comparison between CJC-1295 and sermorelin is largely structural. Sermorelin is GRF(1-29), the unmodified 29-amino-acid fragment; it acts at the same GHRH receptor but is cleared quickly because it lacks the stabilizing changes. CJC-1295 is the same fragment, reinforced: the modified GRF(1-29) substitutions modestly extend its half-life, and the DAC version extends it dramatically through albumin binding. Both are GHRH-class growth hormone secretagogues and share a mechanism; what differs is durability, which is precisely the property CJC-1295 research has set out to characterize.
There are several considerations that shape any interpretation of CJC-1295 research. There is no approved therapeutic indication, and the compound is not characterized for human use. The long-term consequences of sustained GHRH receptor stimulation, including effects on the feedback architecture of the axis and on IGF-1 over time, are not well characterized even in preclinical models. Much of the work to date is preclinical, independent replication is limited, and the purity and identity of material vary across sources, which matters for any laboratory study using research-grade CJC-1295. Overall, its mechanism is well grounded and the pharmacokinetic profile is distinctive, but the evidence base remains limited.
CJC-1295 is a modified GHRH analog whose defining trait is engineered longevity: a stabilized GRF(1-29) core, optionally tethered to albumin via the DAC, acting at the GHRH receptor to drive GH and IGF-1 output over days rather than minutes in preclinical models. The preclinical work is coherent and the pharmacokinetic rationale is clear, but the overall evidence base remains limited, with no approved indication. Material referenced here is intended for laboratory research use only, and the findings describe what has been studied in preclinical systems, not what any individual should expect.
CJC-1295 (No DAC) is available for laboratory research from Pure Peptides. View Product →
References
WRITTEN BY
Dr. Martina Rossi
PhD — Scientific Contributor and Reviewer
Dr. Martina Rossi holds a PhD from Universite Grenoble Alpes, where her doctoral research examined the vascular functions of Bone Morphogenetic Proteins in knockout mouse models. Her published work spans cell and molecular biology, vascular biology, and gene therapy, with peer-reviewed contributions appearing in journals including Cardiovascular Research, Scientific Reports, and Brain Sciences. Dr. Rossi serves as Scientific Contributor and Reviewer for the Pure Peptides research content program, independently reviewing articles for scientific accuracy.
View team profile →
An evidence-based overview of Ipamorelin research: its selective GHS-R1a mechanism, comparison with GHRP-6, and what preclinical studies show about growth hormone secretion.
